At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.
Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.
Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
Location: United States, New York
Employees: 51-200
Total raised: $125M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | RA Capital... | racap.com |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2019 | Series B | $50M | - |
| 08.03.2018 | Series A | $75M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 11.09.2020 | GSK and J&J alum Vijay Reddy to take control of R&... | Vijay Reddy → Vijay Reddy was seeking a return to the US when he left his role as CMO at Lon... | endpts.com... |
| 28.03.2019 | Daily funding roundup - March 28th, 2019 | BillionToOne raised $15M; Polyneuron Pharmaceuticals secured $22.6M;Prevail Therapeutics lands $50M ... | vator.tv/n... |
| 28.03.2019 | Prevail Therapeutics Secures $50M in Series B Financing | Prevail Therapeutics, Inc., a New York, NY-based gene therapy company developing Adeno-Associated Vi... | finsmes.co... |
| 27.03.2019 | Prevail Therapeutics Secures $50 Million in Series B | NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AA... | citybizlis... |
| 27.03.2019 | Prevail Therapeutics raises $50M for gene therapy in Parkins... | According to its website, the company’s focus is on developing adeno-associated viral vector-based g... | medcitynew... |
| 17.03.2019 | Prevail Therapeutics Secures $50 Million in Series B Financi... | - | orbimed.co... |
| 08.03.2018 | Prevail Therapeutics Announces $75 Million Series A | NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing ... | archive.ci... |
| 08.03.2018 | Prevail Therapeutics Raises $75M in Series A Financing | Prevail Therapeutics, Inc., a biotechnology company developing gene therapies for patients with Park... | finsmes.co... |
| 08.03.2018 | Prevail Therapeutics Nabs $75M | NEW YORK, NY, Prevail Therapeutics today announced a $75 million Series A financing. >> Cli... | vcnewsdail... |
| 08.03.2018 | Prevail Therapeutics Announces $75 Million Series A | NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing ... | citybizlis... |
Show more